药捷安康-B(02617)：替恩戈替尼片获国家药品监督管理局批准纳入优先审评品种名单

Core Viewpoint - The company ZhiJie AnKang-B (02617) has received approval from the National Medical Products Administration (NMPA) for its drug, Tiengoni, to be included in the priority review list for the treatment of advanced, metastatic, or unresectable cholangiocarcinoma in adult patients who have previously received at least one systemic therapy and FGFR inhibitor treatment [1] Group 1 - Tiengoni has been recognized by NMPA as a breakthrough therapy for cholangiocarcinoma [1] - The indication for Tiengoni is specifically for adult patients with advanced, metastatic, or unresectable cholangiocarcinoma who have undergone prior systemic treatment [1]